Navigate
X
    QualityStocks
  • 16 years ago

Allos Therapeutics, Inc. (NASDAQ: ALTH)

Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company, is committed to developing and commercializing innovative small molecule drugs for the treatment of cancer. Pralatrexate (PDX), the Company’s lead product candidate, is a novel antifolate currently in a pivotal Phase 2 (PROPEL) trial. RH1, a targeted chemotherapeutic agent, is Allos Therapeutics’ other product candidate and is currently being evaluated in a Phase 1 trial. For further information, visit the Company’s web site at www.allos.com.

Tags Rodman & Renshaw
Related Post
  1. QualityStocksNewsBreaks – Nightfood Holdings Inc. (NGTF) Leading Hospitality Tech Revolution with Innovative Solutions

    Nightfood Holdings (OTCQB: NGTF) is modernizing the hospitality industry with its AI-driven robotics solutions and innovative…

  2. QualityStocksNewsBreaks – SolarBank Corp.’s (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Vision in Action: Building the Grid of Tomorrow

    Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a…

  3. QualityStocksNewsBreaks – ROTH Conference Marks a Quarter-Century of Community in Dana Point

    The 37th Annual ROTH Conference drew thousands of participants from around the globe to Dana…